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Abstract: Oral supplements (OS) support the immune system in fighting upper airways infection.
This study aimed to analyze the effect of Difensil Immuno (DI) on the recurrence of tonsillitis and
fever in children. A multicentric randomized clinical trial was conducted. One-hundred and twenty
children with chronic tonsillitis were randomly assigned to group A, B or control. Patients in group A
were treated with 10 mL of DI for 90 consecutive days, patients in group B underwent treatment with
15 mL of DI for 45 consecutive days. The following data were collected at baseline (T0), T1 and T2:
tonsillitis and fever episodes, tonsillar volume, blood test results. One-way ANOVA was used to
analyze within and between variances. Patients in group A and B statistically improved their clinical
parameters (episode of tonsillitis and fever, tonsillar volume) when compared to control group both
at T1 and T2. However, T1 variances were more consistent in group A than in group B. All patients
in the study groups improved their clinical outcomes. No statistically significant variances were
observed in blood parameters both at T1 and T2. Our results suggest that children treated with DI
had fewer episodes of tonsillitis and fever and a reduction in their tonsillar volume.
Keywords: tonsillitis; treatment; oral supplement; immune system; immune stimulation
1. Introduction
The benefic effect of oral supplements (OS) on the immune system has been shown in patients
suffering from immunodeficiency [1] and in subjects with cancer [2,3]; some specific vitamins, such as
vitamin D, were shown to be able to immunomodulate the immune system of patients with Multiple
Sclerosis by reducing neurodegeneration [4].
Vitamins and antioxidant molecules act on the immune system in different ways; for example,
some of them increase the number of circulating white cells [5], while others empower the reactivity of
the immune response by reducing the level of reactive oxygen species (ROS) known to be dangerous
for the immune system [6].
Most studies with OS are conducted in the adult population and studied these compounds in
non-infectious diseases [1–3]. On the contrary, a few studies have been performed on children suffering
from infectious disease to test the efficacy of OS [7].
Recently, a randomized clinical trial from our group showed that an OS containing Sambucus
nigra, zinc, tyndallized Lactobacillus acidophilus (HA122), arabinogalactans, vitamin D, vitamin E
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and vitamin C (commercial name Difensil Immuno (DI), available in Italy and Europe) could improve
the outcome of children with otitis media [8]. In this study, DI improved the immune response
and reduced the virulence of infection [8].
Each component of DI interacts differently with the immune system. Sambucus nigra inhibits viral
replication and increases the production of inflammatory cytokines; vitamin C reduces the circulating
oxidative species, whose presence negatively impact on the immune response; vitamin D promotes
differentiation of monocytes/macrophages in their active form and increases the chemotactic and
phagocytic capacity of these cells; zinc improves the macrophage phagocytosis ability, the capacity
of antigen presentation and signal transmission between these cells and the other belonging to
the immune-system; selenium is a potent immune-stimulant able to improve T cell proliferation,
natural killer cell activity and several innate immune cell functions. Finally, Lactobacillus acidophilus
and arabinogalactans stimulate the macrophage activity and the production of cytokines.
Children commonly suffer from tonsillitis due to their immature immune system; generally,
antibiotics and corticosteroids are used for the treatment of recurrent episodes [9]. The aim of this
randomized clinical trial was to analyze the effect of DI on the recurrence of tonsillitis and fever
in children.
2. Materials and Methods
This multicentric study was conducted in the Otolaryngology departments of the following
institutions: Santobono-Pausilipon hospital, University of Perugia and University of Palermo from
October 2019 to March 2020. All procedures were approved by the local Institutional Review Board
committee of each hospital and were conducted in accordance with the ethical principles outlined
in the Declaration of Helsinki. The parents of the participating children signed a written informed
consent document authorizing the enrollment of their child in the study.
The three centers used the same criteria and the procedures were standardized before starting
the study.
The inclusion criteria were age <8, at least 3 episodes of tonsillitis per year with fever, Mackenzie
score >2, no previous history of adenoidectomy, no current treatment with antibiotics, no history of
allergies, no diabetes or severe neurological disease.
In each hospital, patients were randomly assigned by a computer to one of three groups: Group A
(GA), Group B (GB) and control Group (CG). GA and GB were treated with OS with immune-stimulating
molecules (Sambucus nigra, zinc, tyndallized Lactobacillus acidophilus (HA122), arabinogalactans,
vitamin D, vitamin E and vitamin C) (Difensil Immuno, Humana Italia S.p.A.).
GA included patients who were treated with 10 mL of DI for 90 consecutive days; GB patients
underwent treatment with 15 mL of DI for 45 consecutive days; and lastly CG did not receive any
therapy. DI was always administered in a single dose in the morning during breakfast.
A dose of 10 mL of DI contains 112 mg of Sambucus nigra, 7.5 mg of zinc, 1 × 107 tyndallized
Lactobacillus acidophilus (HA122), 10 mg of arabinogalactans, 10 mcg of vitamin D, 30 mg of vitamin
E and 90 mg of vitamin C. A dose of 15 mL of DI contains 183 mg of Sambucus nigra, 11.2 mg of zinc,
1.5 × 107 tyndallized Lactobacillus acidophilus (HA122), 15 mg of arabinogalactans, 15 mcg of vitamin
D, 45 mg of vitamin E and 135 mg of vitamin C.
In cases where fever exceeded 38 ◦C, children were treated with paracetamol (500 mg)
and antibiotics if fever persisted over three days.
Patients in the CG followed a “wait and see approach”; children were treated with
anti-inflammatory drugs in cases of a fever episode over 38 ◦C, and antibiotics if the condition
did not resolve within three days. Corticosteroids were never used.
Outcome measures included: number of episodes of tonsillitis during the observation period
and episodes of fever during the period of follow-up, inspection of tonsil aspect and classification
following the Mackenzie classification (Figure 1), red cell count, white cell count, hemoglobin (Hb),
Nutrients 2020, 12, 1637 3 of 10
polymerase chain reaction (PCR) value, erythrocyte sedimentation rate (ESR), antistreptolysin O titer
(ASLOT), pro-calcitonin, rheumatologic test (RT).
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Group B included 41 children, average age = 6 years (SD: 2.5; CI: 3–12), 22 were females and 19 males. 
Control group included 39 children, average age = 5.6 years (SD: 2.3; CI 95%: 3–12), 20 females and 
19 males. None of the patients underwent antibiotic therapy, 15 days being included in the study for 
all the observation period up to one week after the end of the study. 
All patients completed the study and none of them dropped or missed follow-up visits. 
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Statistical Analysis
The statistical analysis as perfor ed using STATA®. ne- ay A VA as used to evaluate
the scores variation ithin each group (GA, GB and CG) at three ti e points (T0, T1 and T2) for the
nu ber of episodes of tonsillitis and fever. The same test was repeated to evaluate the variance of the
tonsils (Mackenzie) and the blood parameters. A Bonferroni-Holms ad hoc test was performed for
each one-way ANOVA. A p value < 0.05 was considered statistically significant.
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3. Results
3.1. Treatment Results “within” Group Comparison
3.1.1. Group A
None of the patients needed antibiotics treatment (Figure 2 and Table 1).
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Statistically significant variances were observed between GA, GB and CG for the following 
parameters: 
  
2. Variation within each group by comparing T0, T1 and T2 for episodes of tonsillitis, Mackenzie
Score a d episodes of fever.
Table 1. Average of clinical data in Group A observed at the three different follow-up visits.
Group A T0 T1 T2
Episodes of tonsillitis 6.5 (SD: 1;CI 95%:4–8)
3.9 (SD: 1;
CI 95%:2–5)
2.8 (SD: 0.9;
CI 95%:1–4)
Mackenzie Score 3.6 (SD: 0.5;CI 95%:3–4)
2.5 (SD: 1;
CI 95%:1–4)
2.2 (SD: 0.7;
CI 95%: 1–3)
Episodes of fever 4 (SD: 1CI 95%: 4–8)
2 (SD: 0.7;
CI 95%: 1–3)
1 (SD: 0.6;
CI 95%: 0–2)
Statistically significant variations were observed by comparing T0, T1 and T2 follow-up for the
following parameters:
(1) Number of tonsillitis episode (ANOVA: p < 0.0001) between T0 and T1 (BH: p < 0.0001), between
T0 and T2 (BH: p < 0.0001) and T1 and T2 (BH: p < 0.0001).
(2) Mackenzie score (ANOVA: p < 0.0001). In particular a significant variance was observed between
T0 and T1 (HB: p < 0.0001), T0 and T2 (HB: p < 0.0001). No statistically significant variances were
observed between T1 and T2 (HB: p = 0.3).
(3) Number of fever episode (ANOVA: p < 0.0001). The variance was statistically significant by
comparing T0 and T1 (HB: p < 0.0001), T0 and T2 (HB: p < 0.0001) and T1 and T2 (HB: p < 0.0001).
No statistically significant variations were observed by comparing children at T0, T1 and T2 for the
following parameters: red cell count (ANOVA: p = 1), white cell count (ANOVA: p = 1), Hb (ANOVA:
p = 1), PCR value (ANOVA: p = 0.6), ESR (ANOVA: p = 0.4), ASLOT (ANOVA: p = 1), pro-calcitonin
(ANOVA: p = 0.9), RT (ANOVA: p = 1).
3.1.2. Group B
None of the patients were treated with antibiotics (Figure 2 and Table 2).
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Table 2. Average of clinical data in Group B observed at the three different follow-up visits.
Group B T0 T1 T2
Episodes of tonsillitis 5,2 (SD: 1.2CI 95%: 4–8)
4 (SD: 1.1;
CI 95%: 2–7)
3.3 (SD: 0.9;
CI 95%: 2–5)
Mackenzie Score 3.5 (SD: 0,6CI 95%:2–4)
3 (SD: 0.6;
CI 95%:2–4)
2.5 (SD: 0.5;
CI 95%:2–4)
Episodes of fever 4 (SD 0.1CI 95%: 4–8)
2,3 (SD: 0.7;
CI 95%:1–3)
1.7 (SD: 0.8;
CI 95%:1–3)
Statistically significant variations were observed by comparing T0, T1 and T2 follow-up for the
following parameters:
(1) Number of tonsillitis episode (ANOVA: p < 0.0001) between T0 and T1 (BH: p < 0.0001), between
T0 and T2 (BH: p < 0.0001). No statistically significant variances were observed between T1 and
T2 (HB: p = 0.07).
(2) Mackenzie score (ANOVA: p < 0.0001). In particular, a significant variance was observed between
T0 and T2 (HB: p < 0.0001) and between T1 and T2 (HB: p = 0.01). No statistically significant
variances were observed between T0 and T1 (HB: p = 0.06).
(3) Number of fever episode (ANOVA: p = 0.002). The variance was statistically significant by
comparing T0 and T1 (HB: p < 0.01), T0 and T2 (HB: p < 0.01) and T1 and T2 (HB: p < 0.01).
No statistically significant variations were observed by comparing children at T0, T1 and T2 for the
following parameters: red cell count (ANOVA: p = 1), white cell count (ANOVA: p = 1), Hb (ANOVA:
p = 1), PCR value (ANOVA: p = 0.9), ESR (ANOVA: p = 0.5), ASLOT (ANOVA: p = 1), pro-calcitonin
(ANOVA: p = 0.9), RT (ANOVA: p = 1).
3.1.3. Control Group
Fifty per-cent of children needed antibiotics treatment (Figure 2 and Table 3).
Table 3. Average of clinical data in group B observed at the three different follow-up visits.
Control Group T0 T1 T2
Episodes of tonsillitis 4.5 (SD: 0.9CI 95%: 3–6)
4.1 (SD: 0.9
CI 95%:2–5)
4.1 (SD: 1;
CI 95%:2–6)
Mackenzie Score 3 (SD: 0.5CI 95%:2–4)
3 (SD: 0.6
CI 95%:2–4)
3 (SD: 0.6
CI 95%:2–4)
Episodes of fever 2.6 (SD: 0.8CI 95%: 4–8)
2.4 (SD: 0.6
CI 95%:2–4)
2.2 (SD: 0.8
CI 95%:1–4)
No statistically significant variations were observed by comparing children at T0, T1 and T2 for
the following parameters: number tonsillitis episodes between the three follow-up (ANOVA: p = 0.2),
Mackenzie scores (ANOVA: p= 0.9), fever episodes (ANOVA: p= 0.2) red cell count (ANOVA: p= 1), white
cell count (ANOVA: p = 1), Hb (ANOVA: p = 1), PCR value (ANOVA: p = 0.6), ESR (ANOVA: p = 0.9),
ASLOT (ANOVA: p = 1), pro-calcitonin (ANOVA: p = 0.7), RT (ANOVA: p = 1).
3.2. Treatment Results “between” Group Comparison
Statistically significant variances were observed between GA, GB and CG for the
following parameters:
3.2.1. Comparison at T1
(1) Number of tonsillitis episode (ANOVA: p < 0.0001). We observed statistically significant variances
between GA (average: 3.9; SD: 1; CI 95%: 2–5) and CG (average: 4.1; SD: 0.9; CI 95%: 2–5)
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(BH: p < 0.0001), but not between GB (average: 4; SD: 1.1; CI 95%: 2–7) and CG (BH: p > 0.05).
Statistically significant variances were observed between GA and GB (HB: p < 0.0001).
(2) Mackenzie score (ANOVA: p < 0.0001). GA (average: 2.5; SD: 1; CI 95%: 1–4) showed statistically
significant variances with CG (average: 3; SD: 0.6; CI 95%: 2–4) (HB: p = 0.0007), while no
statistically significant variances were observed between GB (average: 3; SD: 0.6; CI 95%: 2–4)
and CG (HB: p > 0.05). Statistically significant variance was observed by comparing GA and GB
(HB: p < 0.00001).
(3) Number of fever episode (ANOVA: p = 0.002). The variance was statistically significant by
comparing GA (average: 2; SD: 0.7; CI 95%: 1–3) with CG (average: 2.4; SD: 0.7; CI 95%: 1–4)
(HB: p = 0.001) and GB (average: 2.3; SD: 0.7; CI 95%: 1–4) with CG (HB: p = 0.002). No statistically
significant differences were observed between GA and GB.
No statistically significant variations were observed by comparing GA, GB and CG at T1 for the
following parameters: red cell count (ANOVA: p = 1), white cell count (ANOVA: p = 1), Hb (ANOVA:
p = 1), PCR value (ANOVA: p = 0.7), ESR (ANOVA: p = 0.7), ASLOT (ANOVA: p = 0.9), pro-calcitonin
(ANOVA: p = 0.9), RT (ANOVA: p = 1) (Figure 3).Nutrients 2020, 12, x FOR PEER REVIEW 7 of 10 
 
 
Figure 3. Differences of the analyzed variables between Group A, Group B and Control Group. 
Patients in Group A obtained a statistically significant improvement from T0 as detailed in the results. 
4. Discussion 
Our results show that DI reduced the recurrence of tonsillitis and the fever episodes over a 
period of three months and reduced the average volume of tonsils. Furthermore, children who used 
DI never needed antibiotics treatment. Despite these clinical results, the use of OS did not modify the 
blood parameters of inflammation (PCR, ESR and pro-calcitonin). However, the supplement did not 
affect the other blood parameters. 
All patients (“between analysis”), independently from the therapeutic scheme used, showed a 
better outcome than CG, supporting the use of DI as a stimulator of natural immune answers in 
children. 
Patients treated with 10 mL of OS for 90 consecutive days (GA) showed an improvement after 
45 days, while patients who underwent 15 mL × 45 days (GB) significatively improved their outcome 
after 90 days. This result showed that the use of a low dosage for a longer period could reduce the 
episode and the severity of tonsillitis better than a higher dosage for a short time, as has already been 
shown for other types of OS [10]. 
On the other hand, patients in GB were able to improve their condition after the end of the 
treatment; it could be speculated that a high dosage, despite less efficiency in the short time, could be 
released slowly [11] and improve patients’ outcomes after treatment suspension. 
The “within” analysis group partially confirmed the observations of the “between groups” 
analysis; in fact, both therapeutic schemes improved patients’ outcomes. 
Patients in GA showed improvements in all outcomes (episode of tonsillitis, Mackenzie score 
and fever episode) after 45 days of treatment and this improvement was consistent at the second 
follow-up (90 days); children in GB presented a reduced number of tonsillitis cases and fever episodes 
at T1 without a statistically significant change in the tonsil volume; this outcome improved at T2. In 
addition, patients in GB showed a further reduction of tonsillitis and fever episodes after 90 days, by 
reaching results similar to those observed in GA. 
We speculate that the delay in tonsil volume reduction in GB could be related to the high 
concentration of DI, which stimulates an increase in the local immune response [12] with consequent 
persistence of tonsillar hypertrophy. This initial over-stimulation of white cells in the Waldeyer ring 
could explain the improvement observed in these patients after the end of oral supplementation. We 
previously showed the efficacy of this specific OS to improve the immune answer in the Waldeyer 
ring and to determine an important improvement of otitis media in children [8]. 
Figure 3. Differences of the nalyzed variables between A, Group B and Control Group. Patients
in Group A obtained a st tistically sign ficant improvem nt from T0 as detailed in the r sults.
3.2.2. Comparison at T2
(1) Number of tonsillitis episode (ANOVA: p < 0.0001). By comparing GA (average: 2.8; SD: 0.8;
CI 95%: 1–4) and CG (average: 4.1; SD: 1; CI 95%: 2–6) we observed statistically significant
variances at T2 (HB: p < 0.0001) and the same results were observed when comparing GB (average:
3.3; SD: 0.9; CI 95%: 2–5) with CG (HB: p = 0.0002). No statistically significant variances were
observed between GA and GB.
(2) Mackenzie score (ANOVA: p < 0.0001). GA (average: 2.3; SD: 0.7; CI 95%: 1–3) showed statistically
significant variances with CG (average: 3; SD: 0.6; CI 95%: 2–4) at T2 (HB: p = 0.0001), as well
as GB (average: 2.5; SD: 0.5; CI 95%: 2–3) versus CG (HB: p = 0.01). A statistically significant
variance was observed by comparing GA and GB (HB: p = 0.003).
(3) Number of fever episode (ANOVA: p = 0.002). The variance was statistically significant by
comparing GA (average: 1.3; SD: 0.6; CI 95%: 0–2) and CG (average: 2.2; SD: 0.9; CI 95%: 1–3) at
T2 (HB: p = 0.001) and GB (average: 1.7; SD: 0.7; CI 95%: 1–3) and CG at T2 (HB: p = 0.002). No
statistically significant differences were observed between GA and GB.
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No statistically significant variations were observed by comparing GA, GB and CG at T2 for the
following parameters: red cell count (ANOVA: p = 1), white cell count (ANOVA: p = 1), Hb (ANOVA:
p = 1), PCR value (ANOVA: p = 0.7), ESR (ANOVA: p = 0.7), ASLOT (ANOVA: p = 0.9), pro-calcitonin
(ANOVA: p = 0.9), RT (ANOVA: p = 1) (Figure 3).
4. Discussion
Our results show that DI reduced the recurrence of tonsillitis and the fever episodes over a period
of three months and reduced the average volume of tonsils. Furthermore, children who used DI never
needed antibiotics treatment. Despite these clinical results, the use of OS did not modify the blood
parameters of inflammation (PCR, ESR and pro-calcitonin). However, the supplement did not affect
the other blood parameters.
All patients (“between analysis”), independently from the therapeutic scheme used, showed
a better outcome than CG, supporting the use of DI as a stimulator of natural immune answers
in children.
Patients treated with 10 mL of OS for 90 consecutive days (GA) showed an improvement after
45 days, while patients who underwent 15 mL × 45 days (GB) significatively improved their outcome
after 90 days. This result showed that the use of a low dosage for a longer period could reduce the
episode and the severity of tonsillitis better than a higher dosage for a short time, as has already been
shown for other types of OS [10].
On the other hand, patients in GB were able to improve their condition after the end of the
treatment; it could be speculated that a high dosage, despite less efficiency in the short time, could be
released slowly [11] and improve patients’ outcomes after treatment suspension.
The “within” analysis group partially confirmed the observations of the “between groups” analysis;
in fact, both therapeutic schemes improved patients’ outcomes.
Patients in GA showed improvements in all outcomes (episode of tonsillitis, Mackenzie score and
fever episode) after 45 days of treatment and this improvement was consistent at the second follow-up
(90 days); children in GB presented a reduced number of tonsillitis cases and fever episodes at T1
without a statistically significant change in the tonsil volume; this outcome improved at T2. In addition,
patients in GB showed a further reduction of tonsillitis and fever episodes after 90 days, by reaching
results similar to those observed in GA.
We speculate that the delay in tonsil volume reduction in GB could be related to the high
concentration of DI, which stimulates an increase in the local immune response [12] with consequent
persistence of tonsillar hypertrophy. This initial over-stimulation of white cells in the Waldeyer ring
could explain the improvement observed in these patients after the end of oral supplementation. We
previously showed the efficacy of this specific OS to improve the immune answer in the Waldeyer ring
and to determine an important improvement of otitis media in children [8].
Overall, our results suggest that a long-term treatment with 10 mL of OS is better than a shorter
one, although the short time, high-dosage therapeutic scheme maintains a very good efficacy after
treatment suspension.
We speculate that DI could have stimulated the immune system function [13–16] thanks to the
synergic effect of its different components. S. nigra, which has been confirmed as an efficient molecule
for inhibiting viral replication in the early stages of infection [17] was fundamental to reduce the
episode of tonsillitis and consequently to decrease fever recurrence. A, C, D and E vitamins contributed
to the action of the S. nigra by increasing mucosal IgA (A and E) [18,19] and by actively stimulating
macrophage and lymphocyte activity [5,20], thus making children more resistant to viral infection in
the upper respiratory tract (URT). The reduction of the number of infections progressively allowed the
reduction of tonsil volume.
Lactobacillus acidophilus, another component of the OS, can improve the immune response
thanks to the reduction of concentration of ROS, known as a depressor of the immune system [6].
In addition, lactobacillus inhibits the penetrance of virus inside the cells by further contributing to
Nutrients 2020, 12, 1637 8 of 10
protect URT from common viral infection [21] and has the capacity to inhibit the adhesion and the
growth of gram-negative bacteria [22] by protecting the subject from viral and bacterial aggression.
The results of immune-stimulating OS treatment in children reported in this study are consistent
with the results observed in adults [23–25] and with a previous study conducted in children in which
the authors showed the efficacy of this OS due to its ability to reduce the volume of the adenoid tissue
indicative of the resolution of the infective/inflammatory process [26].
However, because of the short duration of this study, additional studies with a longer follow-up
are necessary to confirm these preliminary results. In fact, longer studies could evaluate the effect
of DI on immune-system cells and could evaluate whether DI could be tolerated for longer periods
without interruption.
5. Conclusions
Our study results suggest that OS can be a valid tool to reduce the recurrence of tonsillitis and
fever episodes in children. In our patients, this natural compound showed a positive effect on the
chronic disease without side effects. Although this is the first clinical trial conducted on children with
recurrent tonsillitis to evaluate the efficacy of DI, we already successfully tested this compound on
children with otitis media.
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